Abbott’s Recommitment To Core Diagnostics Is Rewarded By Strong Returns
This article was originally published in The Gray Sheet
Executive Summary
Abbott has a newfound loyalty to its long-struggling core diagnostics business, which the company was at the brink of unloading just last year, and the division has responded with a dramatic turnaround
You may also be interested in...
FDA Warning Letter Cites Quality Control Issues At Abbott Diabetes Care
Abbott's Diabetes Care division did not follow internal protocols for quality control testing of its FreeStyle blood glucose monitoring systems and FreeStyle Navigator continuousglucose monitoring systems, FDA alleged in a July 2 warning letter to the firm
FDA Warning Letter Cites Quality Control Issues At Abbott Diabetes Care
Abbott's Diabetes Care division did not follow internal protocols for quality control testing of its FreeStyle blood glucose monitoring systems and FreeStyle Navigator continuousglucose monitoring systems, FDA alleged in a July 2 warning letter to the firm
A Compliant Abbott Channels More Funds Into Core Diagnostics R&D
Now that Abbott is in the final throes of a 1999 FDA consent degree, the company's core chemistry and immunoassay diagnostics unit says it has freed up some more funds for research and development